『Mounjaro Heart Protection: What You Need to Know』のカバーアート

Mounjaro Heart Protection: What You Need to Know

Mounjaro Heart Protection: What You Need to Know

無料で聴く

ポッドキャストの詳細を見る
概要

FDA Expands Mounjaro Approval for Heart Protection (Aug 28, 2026): What the SURPASE Trial Means for Type 2 Diabetes Dr. Kulmeet Kundlas explains the FDA’s August 28, 2026 approval change for Mounjaro (tirzepatide), stating it is now officially approved to reduce the risk of future heart attack and stroke in addition to lowering A1C, supporting weight loss, and improving related metabolic factors. He reviews the SURPASE trial, a large study across 30+ countries with about 13,000 patients, comparing Mounjaro to Trulicity and finding Mounjaro similarly protective and about 1% more effective (13% vs 12%) despite participants already maximizing blood pressure, cholesterol, lifestyle, and standard therapies. He discusses inflammation as a key mechanism via GLP-1 and GIP receptor activity, notes common GI side effects and contraindication with medullary thyroid carcinoma, and emphasizes benefits depend on continued diet, exercise, resistance training, and high-protein intake.

adbl_web_anon_alc_button_suppression_t1
まだレビューはありません